Tech Company Financing Transactions
RS BioTherapeutics Funding Round
RS BioTherapeutics closed a $3 million venture capital round on 9/26/2022. Investors included private investors.
Transaction Overview
Company Name
Announced On
9/26/2022
Transaction Type
Venture Equity
Amount
$3,000,000
Round
Undisclosed
Investors
Proceeds Purpose
The company intends to use the funds to expand operations and its development efforts.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
157 Baltimore St.
Cumberland, MD 21502
USA
Cumberland, MD 21502
USA
Phone
Undisclosed
Website
Email Address
Not Recorded
Overview
The mission of RS BioTherapeutics is to harness our strong and thorough understanding of the Endocannabinoid System in the research, development, and commercialization of forward-thinking interventions to address chronic and acute pulmonary inflammation-based diseases.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Dean Hart
Chief Scientific Officer
Debra Kimless
VP - Administration
Michael Guzman
VP - Bus. Development
Justin Molignoni
Browse more venture capital transactions:
Prev: 9/26/2022: Equalbase venture capital transaction
Next: 9/26/2022: Faraday Future venture capital transaction
Share this article
Where The Data Comes From
We do our best to record every notable VC transaction. VC investment data records on this site are sourced from publicly available VC deal announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs